efflux pumps in E. coli did not affect the ciprofloxacin MIC. 31 The deletion of transcriptional ciprofloxacin MIC. The only study in our collected experimental data to investigate deletion of 2 2 3 acrR showed that the MIC tripled after the repressor was deleted. 51 Nine studies investigated the 2 2 4 effects of marR deletion or mutation, which reported a median fold increase in ciprofloxacin MIC 2 2 5 of 4 (range 1.5-218x fold increase). 30, 51, 52, 54, [58] [59] [60] accumulation of other mutations, and were shown to increase the ciprofloxacin MIC of a wild 2 2 8 type E. coli by 1.5-3 fold change ( Table 2 ). The mutations in rpoB were shown to increase 2 2 9
ciprofloxacin MIC by upregulating the expression of mdtK (also known as ydhE).
Two experimental studies reported mutations in efflux pump operons, influencing ciprofloxacin MIC. The first mutation was Ala12Ser in soxS, leading to higher expression of acrB, in turn 2 3 2 leading to a ciprofloxacin MIC fold increase of 4. 32 The second mutation was a Gly288Asp 2 3 3 mutation in acrB itself, conferring a 16.7 fold increase in ciprofloxacin MIC (Table 2) . 61 This acrB 2 3 4 mutation however increased susceptibility to other antimicrobials.
3 5
Plasmid-encoded efflux pump genes oqxAB and qepA 2 3 6
In addition to chromosomally-encoded efflux pumps, the presence of plasmid-encoded efflux 2 3 7
pump genes oqxAB and qepA has been shown to increase ciprofloxacin MIC in E. coli.
34,35
2 3 8
oqxAB confers a median fold increase in MIC of 7.5 (range 2-16x fold increase) 35, [62] [63] [64] , while 2 3 9
qepA confers a median fold increase of 4.5 (range 2-31x fold increase, Table 2 ). MIC fold increase differed per qnr allele (Table 2) . A plasmid mediated mutant aac(6')Ib gene that decreased fluoroquinolone susceptibility in E. increase in ciprofloxacin MIC of 6.9 (range: 1-62.5x fold increase, Table 2 ).
52,71-76
The most recently discovered ciprofloxacin resistance determinant in E. coli is crpP, a plasmid- The fold change in MIC of each included experimental isolate was plotted, stratified for the fold changes which were on average higher than the fold changes observed as a result of the Comparison of experimental and observational data
We compared the findings from the experimental data with susceptibility test results and and marR genes were shown to result in no to low fold changes in ciprofloxacin MIC, we added five observational studies that fulfilled all inclusion and exclusion criteria except testing for the the exception for the reported MICs for E. coli strains solely harbouring aac(6')Ib-cr (Table 3) . We also examined if certain combinations of resistance mechanisms were more prevalent than observed resistance determinants showed that gyrA (Ser83, Asp87) and parC (Ser80) mutations were positively correlated with each other. Additionally, these three mutations were shown to inversely correlate with the presence of qnrB and qnrS genes in our observational data. This inverse correlation was not observed with other frequently reported plasmid-mediated resistance 2 9 7 determinants such as aac(6')Ib-cr ( Figure 4 ). In order to get a global picture of the mutation landscape associated with ciprofloxacin showed the highest number of matching edges and nodes among the strains available in String
database. We noted that plasmid-associated genes like oqxAB and the qnr gene family were not
described by interactomes in general, since interactomes mostly describe the core genome.
Moreover, some genes (such as yohG) could not be mapped because they are not present in E.
Of the 43 selected genes, 31 (72%) mapped to the PPI network, resulting in a fully connected were shown to interact with efflux pump genes such as acrA, acrB, acrD, acrF and tolC. Also,
the physical interactions between gyrA, gyrB and parC were depicted in the network. amounting to a total of 604 isolates. Ciprofloxacin MIC in E. coli is largely affected by target
mutations in specific residues in gyrA (Ser83 and Asp87) and parC (Ser80), conferring median
MIC fold increases ranging from 24 for single Ser83Leu (gyrA) mutants to 1533 for triple
Ser83Leu, Asp87Asn/Gly (gyrA) Ser80Ile/Arg (parC) mutants. However, accumulation of
multiple resistance determinants, including those representing other resistance mechanisms,
can increase ciprofloxacin MIC even further, up to MIC fold increases of 4000.
Beside the MIC fold changes that are conferred by resistance determinants, it is important to 3 2 9
consider how these genetic resistance determinants are acquired. The SOS response is an
important driver of mutation after DNA damage is induced by quinolones such as ciprofloxacin. ciprofloxacin, RecA will bind ssDNA that is a result of the DNA damage. The activated RecA in of SOS genes and thus the SOS response. This SOS response induces mutations, among
others, through DNA damage repair performed by error-prone DNA polymerases. Currently, four ways are known in which the SOS response affects ciprofloxacin resistance in E. coli. First, the SOS response induces a higher mutation rate, making it more likely that resistance genes when E. coli is grown in the presence of ciprofloxacin. After mutagenesis through mechanisms such as the SOS response, the fitness of the mutant
indicates how likely the bacterium is to survive. In absence of ciprofloxacin, gyrA mutations and determinants. 48, 51, 59, 67, 75 Additionally, mutations in gyrA and parC show positive epistasis, as the
MIC fold change of the triple Ser83Leu, Asp87Asn (gyrA) and Ser80Ile (parC) mutant is higher are the most common ciprofloxacin resistance determinants observed in E. coli.
Notably, other combinations of resistance determinants also show positive epistatic effects, with qnrB, but the opposite effect for target alteration mutations with qnrS in terms of conferred
MIC. The complex relation between gyrA/parC mutations and qnr genes is further illustrated by our fitness cost conferred by an antimicrobial resistance gene to an E. coli strain can be influenced by genes that do not directly play a role in antimicrobial resistance. By mapping the selected genes onto a known E. coli interactome, we found a clear association
between their role in ciprofloxacin resistance and their position in the network, with a significant suggest that their role in resistance should be more deeply investigated. Despite its comprehensiveness our study has certain limitations. First, gene expression data are
not included in this review because our study aims at prediction of MIC on the basis of a DNA have been reported sparsely in the experimental data. Therefore, the comparison of experimental and observational data for these combinations of resistance determinants is 3 9 4 impossible using this dataset. Finally, only currently known ciprofloxacin resistance determinants 3 9 5 could be included in this report. The very recent discovery of crpP suggests that more resistance 3 9 6 determinants or resistance mechanisms are still waiting to be discovered. 43 Additionally,
complex mutation patterns influencing ciprofloxacin resistance through unknown pathways may
exist, but current research methods do not usually detect these kinds of effects. One possible solution for the issues described above would be the use of advanced machine 4 0 0 learning algorithms to predict ciprofloxacin resistance. These algorithms should be able to 4 0 1 associate large quantities of sequence data with phenotypic metadata in an unbiased manner. Enterobacteriaceae species and the results can thus not be directly compared with the data 4 0 7
presented here for E. coli alone. This is exemplified by the fact that neither Ser83Phe nor 4 0 8
Ser83Thr (gyrA) were reported in our observational data. For future studies, the data collected We wish to thank the COMPARE consortium for support and helpful discussions. No specific funding has been received for this work. BP was funded through an internal grant None to declare. Published 2018. 1998;42(10):2661-2667. Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob Agents
Chemother. 1997;41(1):85-90. five times in both experimental and observational data. The EUCAST epidemiological cut-off for 
